A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Melanoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Has histologically or cytologically confirmed melanoma. 2. Has unresectable Stage Ill or Stage IV melanoma. 3. Has the presence of at least 1 measurable ·lesion by CT or MRI
You may not be eligible for this study if the following are true:
-
1. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy. 2. Has a known additional malignancy that is progressing or requires active treatment within the past 2 years. 3. Has known active CNS metastases and/or carcinomatous meningitis.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.